The crystal structure of cruzain: a therapeutic target for Chagas' disease.

@article{Mcgrath1995TheCS,
  title={The crystal structure of cruzain: a therapeutic target for Chagas' disease.},
  author={M. Mcgrath and A. Eakin and J. Engel and J. McKerrow and C. Craik and R. Fletterick},
  journal={Journal of molecular biology},
  year={1995},
  volume={247 2},
  pages={
          251-9
        }
}
Trypanosoma cruzi, a protozoan parasite, is the etiologic agent of American trypanosomiasis or Chagas' disease. Chagas' disease afflicts more than 24 million individuals in South and Central America producing a debilitating life-long disease. It is the leading cause of heart failure in many Latin American countries. Currently, there is no satisfactory treatment for this parasitic infection. Cruzain (also known as cruzipain, gp 57/51), the major cysteine protease present in T. cruzi, is critical… Expand
In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi
Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection
Aryl ureas represent a new class of anti-trypanosomal agents.
An insight on targets and patented drugs for chemotherapy of Chagas disease.
A decade of targets and patented drugs for chemotherapy of Chagas disease.
  • V. Duschak
  • Medicine, Biology
  • Recent patents on anti-infective drug discovery
  • 2011
Update on relevant trypanosome peptidases: Validated targets and future challenges.
...
1
2
3
4
5
...